NCT06176365: An ongoing trial by Boehringer Ingelheim
This trial is ongoing. It must report results 11 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06176365 |
|---|---|
| Title | A Phase III, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of Survodutide Administered Subcutaneously Compared With Placebo in Patients With Obesity Disease in Japanese |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 16, 2024 |
| Completion date | Dec. 3, 2025 |
| Required reporting date | Dec. 3, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |